Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | METAP1 | P53582 | 2/20 | 0.72 |
| ▸ | SIGMAR1 | Q99720 | 5/20 | 0.71 |
| ▸ | HTR1A | P08908 | 2/20 | 0.62 |
| ▸ | ACHE | P22303 | 3/20 | 0.56 |
| ▸ | HTR7 | P34969 | 2/20 | 0.54 |
| ▸ | HTR2C | P28335 | 2/20 | 0.49 |
| ▸ | DRD2 | P14416 | 1/20 | 0.49 |
| ▸ | HTR2A | P28223 | 1/20 | 0.49 |
| ▸ | HTR2B | P41595 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30423421 | 0.93 | METAP1 (0.74) | METAP1SIGMAR1HTR1AACHEHTR2C | |
| Hydrochloric Acid SCHEMBL29583950 | 0.91 | METAP1 (0.74) | METAP1SIGMAR1HTR1AACHEHTR2C | |
| SCHEMBL5471012 | 0.84 | METAP1 (1.00) | METAP1SIGMAR1HTR1AACHEHTR7 | |
| SCHEMBL11633828 | 0.79 | HTR2C (0.72) | SIGMAR1HTR1AHTR2CDRD2HTR2A | |
| SCHEMBL27646285 | 0.79 | SIGMAR1 (0.68) | METAP1SIGMAR1HTR1AACHEHTR2C | |
| SCHEMBL15700140 | 0.77 | ACHE (0.56) | METAP1SIGMAR1HTR1AACHEHTR7 | |
| SCHEMBL6492064 | 0.77 | SIGMAR1 (0.70) | METAP1SIGMAR1HTR1AACHEHTR2C | |
| SCHEMBL10033952 | 0.76 | SIGMAR1 (0.70) | SIGMAR1HTR1AACHEHTR7 | |
| SCHEMBL11727341 | 0.76 | SIGMAR1 (0.63) | METAP1SIGMAR1HTR1AACHE | |
| Hydrochloric Acid SCHEMBL11736949 | 0.75 | SIGMAR1 (0.62) | METAP1SIGMAR1HTR1AACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7223867-B2 | Preparation of benzosuberonylpiperidine compounds | GLAXOSMITHKLINE S.P.A. (IT) | 2007-05-29 | — | — | US | disclosed |
| US-20050059700-A1 | Preparation of benzosuberonylpiperidine compounds | GLAXOSMITHLINE S.P.A. (IT) | 2005-03-17 | — | — | US | disclosed |
| EP-1442017-A1 | PREPARATION OF BENZOSUBERONYLPIPERIDINE COMPOUNDS | GlaxoSmithKline S.p.A. (IT) | 2004-08-04 | — | — | EP | disclosed |
| WO-2003040099-A1 | PREPARATION OF BENZOSUBERONYLPIPERIDINE COMPOUNDS | GLAXOSMITHKLINE S.P.A. (IT) | 2003-05-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050059700-A1 | Preparation of benzosuberonylpiperidine compounds | CYP2S1, COX6C, CYC1 | METAP1 1130/4885SIGMAR1 219/4885HTR1A 63/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.